Home
>
US Stocks
>
Geron Corporation

Geron Corporation (GERN)

$3.25

+0.12

(+3.83%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on Geron Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 297.0K → 21.0K (in $), with an average decrease of 92.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -100.85M → -38.07M (in $), with an average increase of 164.9% per quarter

Performance

  • $3.21
    $3.51
    $3.25
    downward going graph

    1.16%

    Downside

    Day's Volatility :8.48%

    Upside

    7.41%

    downward going graph
  • $1.18
    $3.84
    $3.25
    downward going graph

    63.69%

    Downside

    52 Weeks Volatility :69.27%

    Upside

    15.36%

    downward going graph

Returns

PeriodGeron CorporationSector (Health Care)Index (Russel 2000)
3 Months
18.61%
-0.5%
-6.7%
6 Months
41.92%
-7.0%
-5.4%
1 Year
132.14%
-4.8%
-6.3%
3 Years
98.17%
26.9%
23.2%

Highlights

Market Capitalization
1.6B
Book Value
$0.64
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.36
PEG Ratio
-2.38
Wall Street Target Price
4.83
Profit Margin
0.0%
Operating Margin TTM
-30357.69%
Return On Assets TTM
-30.08%
Return On Equity TTM
-70.8%
Revenue TTM
494.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-82.89999999999999%
Gross Profit TTM
-93.7M
EBITDA
-149.6M
Diluted Eps TTM
-0.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.38
EPS Estimate Next Year
-0.31
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Geron Corporation(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
2
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 48.62%

Current $3.25
Target $4.83

Company Financials

FY17Y/Y Change
Revenue
1.1M
↓ 82.72%
Net Income
-27.9M
↓ 5.49%
Net Profit Margin
-2.6K%
↓ 2141.88%
FY18Y/Y Change
Revenue
1.1M
↑ 0.09%
Net Income
-27.0M
↓ 3.22%
Net Profit Margin
-2.5K%
↑ 86.79%
FY19Y/Y Change
Revenue
460.0K
↓ 56.85%
Net Income
-68.5M
↑ 153.72%
Net Profit Margin
-14.9K%
↓ 12367.31%
FY20Y/Y Change
Revenue
253.0K
↓ 45.0%
Net Income
-75.6M
↑ 10.31%
Net Profit Margin
-29.9K%
↓ 14986.4%
FY21Y/Y Change
Revenue
1.4M
↑ 450.59%
Net Income
-116.1M
↑ 53.55%
Net Profit Margin
-8.3K%
↑ 21552.75%
Q4 FY21Q/Q Change
Revenue
1.0M
↑ 854.13%
Net Income
-32.0M
↑ 19.93%
Net Profit Margin
-3.1K%
↑ 21414.1%
Q1 FY22Q/Q Change
Revenue
123.0K
↓ 88.17%
Net Income
-30.1M
↓ 5.99%
Net Profit Margin
-24.5K%
↓ 21391.36%
Q2 FY22Q/Q Change
Revenue
73.0K
↓ 40.65%
Net Income
-28.1M
↓ 6.58%
Net Profit Margin
-38.5K%
↓ 14046.52%
Q3 FY22Q/Q Change
Revenue
297.0K
↑ 306.85%
Net Income
-41.1M
↑ 46.0%
Net Profit Margin
-13.8K%
↑ 24694.55%
Q1 FY23Q/Q Change
Revenue
21.0K
-
Net Income
-38.1M
↓ 62.25%
Net Profit Margin
-181.3K%
-
FY17Y/Y Change
Total Assets
110.3M
↓ 15.31%
Total Liabilities
6.5M
↓ 17.19%
FY18Y/Y Change
Total Assets
185.3M
↑ 67.96%
Total Liabilities
7.6M
↑ 15.88%
FY19Y/Y Change
Total Assets
165.5M
↓ 10.67%
Total Liabilities
30.4M
↑ 302.09%
FY20Y/Y Change
Total Assets
270.7M
↑ 63.57%
Total Liabilities
59.8M
↑ 96.89%
FY21Y/Y Change
Total Assets
226.0M
↓ 16.51%
Total Liabilities
99.6M
↑ 66.64%
FY22Y/Y Change
Total Assets
185.2M
↓ 18.07%
Total Liabilities
110.6M
↑ 11.0%
Q4 FY21Q/Q Change
Total Assets
226.0M
↓ 1.34%
Total Liabilities
99.6M
↑ 28.47%
Q1 FY22Q/Q Change
Total Assets
198.4M
↓ 12.22%
Total Liabilities
100.9M
↑ 1.32%
Q2 FY22Q/Q Change
Total Assets
238.2M
↑ 20.03%
Total Liabilities
96.1M
↓ 4.78%
Q3 FY22Q/Q Change
Total Assets
232.6M
↓ 2.33%
Total Liabilities
124.4M
↑ 29.47%
Q4 FY22Q/Q Change
Total Assets
185.2M
↓ 20.39%
Total Liabilities
110.6M
↓ 11.14%
Q1 FY23Q/Q Change
Total Assets
392.1M
↑ 111.72%
Total Liabilities
66.0M
↓ 40.29%
FY17Y/Y Change
Operating Cash Flow
-20.6M
↑ 11.91%
Investing Cash Flow
23.0M
↑ 162.12%
Financing Cash Flow
1.1M
↓ 4.96%
FY18Y/Y Change
Operating Cash Flow
-21.0M
↑ 2.2%
Investing Cash Flow
-77.7M
↓ 438.35%
Financing Cash Flow
93.0M
↑ 8267.96%
FY19Y/Y Change
Operating Cash Flow
-43.8M
↑ 108.62%
Investing Cash Flow
27.4M
↓ 135.26%
Financing Cash Flow
19.5M
↓ 79.03%
FY20Y/Y Change
Operating Cash Flow
-66.7M
↑ 52.07%
Investing Cash Flow
-105.3M
↓ 484.38%
Financing Cash Flow
168.3M
↑ 763.36%
FY21Y/Y Change
Operating Cash Flow
-95.6M
↑ 43.37%
Investing Cash Flow
71.9M
↓ 168.31%
Financing Cash Flow
48.6M
↓ 71.16%
Q4 FY21Q/Q Change
Operating Cash Flow
-22.2M
↓ 2.94%
Investing Cash Flow
8.4M
↓ 254.74%
Financing Cash Flow
19.6M
↑ 20.76%
Q1 FY22Q/Q Change
Operating Cash Flow
-34.0M
↑ 53.26%
Investing Cash Flow
30.4M
↑ 263.74%
Financing Cash Flow
70.6M
↑ 259.3%
Q2 FY22Q/Q Change
Operating Cash Flow
-28.6M
↓ 15.69%
Investing Cash Flow
2.8M
↓ 90.76%
Financing Cash Flow
70.6M
↑ 0.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-29.6M
↑ 3.28%
Investing Cash Flow
9.8M
↑ 250.25%
Financing Cash Flow
4.8M
↓ 93.23%
Q1 FY23Q/Q Change
Operating Cash Flow
-46.4M
↓ 52.59%
Investing Cash Flow
-178.7M
-
Financing Cash Flow
281.0M
↑ 240.72%

Technicals Summary

Sell

Neutral

Buy

Geron Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Geron Corporation
Geron Corporation
36.55%
41.92%
132.14%
98.17%
-28.26%
Moderna, Inc.
Moderna, Inc.
-2.94%
-28.02%
-14.51%
141.93%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.55%
-2.29%
4.58%
33.18%
144.36%
Seagen, Inc.
Seagen, Inc.
-3.62%
59.62%
36.85%
26.49%
248.38%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.76%
4.66%
20.55%
18.48%
112.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Geron Corporation
Geron Corporation
NA
NA
-2.38
-0.38
-0.71
-0.3
0.0
0.64
Moderna, Inc.
Moderna, Inc.
11.28
11.28
0.0
-1.96
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.02
20.02
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.02
27.02
0.41
14.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Geron Corporation
Geron Corporation
Buy
$1.6B
-28.26%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.2B
578.71%
11.28
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
144.36%
20.02
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
248.38%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.7B
112.57%
27.02
35.4%

Institutional Holdings

  • BlackRock Inc

    5.36%

  • State Street Corporation

    5.02%

  • Vanguard Group Inc

    4.43%

  • Vivo Capital, LLC

    3.79%

  • NEA Management Company, LLC

    3.21%

  • TCG Crossover Management, LLC

    2.99%

Corporate Announcements

  • Geron Corporation Earnings

    Geron Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Organization
Geron Corporation
Employees
107
CEO
Dr. John A. Scarlett M.D.
Industry
Health Technology

Discover More

FAQs